Allogeneic CD56-positive CD3-negative Natural Killer Cells (MD Anderson Cancer Center)

N/A

Report date: 2024/07/30 20:00:05

Base Information

Drug NameAllogeneic CD56-positive CD3-negative Natural Killer Cells (MD Anderson Cancer Center)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy
Mechanisms of ActionNatural killer cells stimulants
TargetsUpdating
Therapy Area/IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Megakaryoblastic, Acute +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesThe University Of Texas MD Anderson Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesLeukemia, Myelomonocytic, ChronicLeukemia, Megakaryoblastic, Acute +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A